Cargando…

Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial

Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long‐term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollage...

Descripción completa

Detalles Bibliográficos
Autores principales: Perri, Giorgia, Hill, Tom R, Mathers, John C, Walsh, Jennifer S, Gossiel, Fatma, Winther, Kristian, Frölich, Jacob, Folkestad, Lars, Cold, Søren, Eastell, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087503/
https://www.ncbi.nlm.nih.gov/pubmed/36093566
http://dx.doi.org/10.1002/jbmr.4703
_version_ 1785022362851213312
author Perri, Giorgia
Hill, Tom R
Mathers, John C
Walsh, Jennifer S
Gossiel, Fatma
Winther, Kristian
Frölich, Jacob
Folkestad, Lars
Cold, Søren
Eastell, Richard
author_facet Perri, Giorgia
Hill, Tom R
Mathers, John C
Walsh, Jennifer S
Gossiel, Fatma
Winther, Kristian
Frölich, Jacob
Folkestad, Lars
Cold, Søren
Eastell, Richard
author_sort Perri, Giorgia
collection PubMed
description Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long‐term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollagen type I N‐terminal propeptide (PINP), collagen type I cross‐linked C‐telopeptide (CTX), and bone alkaline phosphatase (BALP) in the short (6 months) and long term (5 years). A total of 481 Danish men and women (60–74 years) were randomized to receive placebo‐yeast versus 100, 200, or 300 μg selenium as selenium‐enriched yeast daily for 5 years. Plasma selenium concentration was measured using inductively coupled plasma mass spectrometry, and BTMs were measured in nonfasted samples at baseline, 6 months, and 5 years. Data were analyzed by ANCOVA to investigate the shape of the dose‐response relationships. Covariates included age, body mass index, baseline selenium status, baseline BTM, smoking, alcohol, supplement use, and medication. Plasma selenium concentration (mean 86.5 μg/d at baseline) increased significantly with increasing selenium supplementation to 152.6, 209.1, and 253.7 μg/L after 6 months and remained elevated at 5 years (158.4, 222.4, and 275.9 μg/L for 100, 200, and 300 μg supplemental selenium/d, respectively (p < 0.001)). There was no change in plasma selenium concentration in the placebo‐treated group. There was no significant effect of selenium supplementation on OC (6 months p = 0.37; 5 years p = 0.63), PINP (6 months p = 0.37; 5 years p = 0.79), CTX (6 months p = 0.91; 5 years p = 0.58) or BALP (6 months p = 0.17; 5 years p = 0.53). The relatively replete baseline selenium status in the study participants may explain this lack of effect. Testing in more deficient populations may provide further insights into the impact of selenium supplementation on bone health. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
format Online
Article
Text
id pubmed-10087503
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-100875032023-04-12 Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial Perri, Giorgia Hill, Tom R Mathers, John C Walsh, Jennifer S Gossiel, Fatma Winther, Kristian Frölich, Jacob Folkestad, Lars Cold, Søren Eastell, Richard J Bone Miner Res Clinical Trial Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long‐term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollagen type I N‐terminal propeptide (PINP), collagen type I cross‐linked C‐telopeptide (CTX), and bone alkaline phosphatase (BALP) in the short (6 months) and long term (5 years). A total of 481 Danish men and women (60–74 years) were randomized to receive placebo‐yeast versus 100, 200, or 300 μg selenium as selenium‐enriched yeast daily for 5 years. Plasma selenium concentration was measured using inductively coupled plasma mass spectrometry, and BTMs were measured in nonfasted samples at baseline, 6 months, and 5 years. Data were analyzed by ANCOVA to investigate the shape of the dose‐response relationships. Covariates included age, body mass index, baseline selenium status, baseline BTM, smoking, alcohol, supplement use, and medication. Plasma selenium concentration (mean 86.5 μg/d at baseline) increased significantly with increasing selenium supplementation to 152.6, 209.1, and 253.7 μg/L after 6 months and remained elevated at 5 years (158.4, 222.4, and 275.9 μg/L for 100, 200, and 300 μg supplemental selenium/d, respectively (p < 0.001)). There was no change in plasma selenium concentration in the placebo‐treated group. There was no significant effect of selenium supplementation on OC (6 months p = 0.37; 5 years p = 0.63), PINP (6 months p = 0.37; 5 years p = 0.79), CTX (6 months p = 0.91; 5 years p = 0.58) or BALP (6 months p = 0.17; 5 years p = 0.53). The relatively replete baseline selenium status in the study participants may explain this lack of effect. Testing in more deficient populations may provide further insights into the impact of selenium supplementation on bone health. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). John Wiley & Sons, Inc. 2022-09-29 2022-11 /pmc/articles/PMC10087503/ /pubmed/36093566 http://dx.doi.org/10.1002/jbmr.4703 Text en © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Trial
Perri, Giorgia
Hill, Tom R
Mathers, John C
Walsh, Jennifer S
Gossiel, Fatma
Winther, Kristian
Frölich, Jacob
Folkestad, Lars
Cold, Søren
Eastell, Richard
Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial
title Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial
title_full Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial
title_fullStr Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial
title_full_unstemmed Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial
title_short Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial
title_sort long‐term selenium‐yeast supplementation does not affect bone turnover markers: a randomized placebo‐controlled trial
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087503/
https://www.ncbi.nlm.nih.gov/pubmed/36093566
http://dx.doi.org/10.1002/jbmr.4703
work_keys_str_mv AT perrigiorgia longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial
AT hilltomr longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial
AT mathersjohnc longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial
AT walshjennifers longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial
AT gossielfatma longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial
AT wintherkristian longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial
AT frolichjacob longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial
AT folkestadlars longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial
AT coldsøren longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial
AT eastellrichard longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial